A randomized, controlled trial comparing topical steroid application to wet versus dry skin in children with atopic dermatitis (AD) - 20/07/16
Abstract |
Background |
Soak and smear (SS), a technique whereby a bath is followed by topical corticosteroid (TCS) application to wet skin, is reported to be a beneficial adjunctive therapy for patients with recalcitrant atopic dermatitis (AD).
Objective |
We evaluated whether SS is of greater benefit than application of TCS to dry skin for the treatment of childhood AD.
Methods |
A randomized, investigator-blinded, controlled study was performed in children with AD. Patients were randomized to apply TCS either via SS (n = 22) or to dry skin (n = 23) for 14 days. The primary outcome was an improvement in the Eczema Area and Severity Index score. Secondary outcomes included assessments of disease burden, pruritus, and sleep; morning cortisol levels; and adverse effects.
Results |
Patients with AD severity who applied TCS via SS or to dry skin improved 84.8% (95% confidence interval 77.5-92.1) and 81.4% (95% confidence interval 70.3-92.4) by Eczema Area and Severity Index score, respectively. There was no statistical difference between the 2 groups (P value = .85).
Limitations |
Small sample size limited the power of our study.
Conclusions |
We did not find that application of TCS to presoaked skin works better than application to dry skin for the treatment of AD in children.
Il testo completo di questo articolo è disponibile in PDF.Key words : atopic dermatitis, bath, corticosteroids, eczema, hydration, soak and smear
Abbreviations used : AD, EASI, SS, TCS
Mappa
| Supported by Yale University School of Medicine James G. Hirsch, MD, Endowed Medical Student Research Fellowship. |
|
| Dr Antaya has been a consultant for the following: Promius, Anacor, Astellas, Ranbaxy, Pierre Fabre, and Hoffman-Laroche Pharmaceuticals. Drs Kohn and Kang have no conflicts of interest to declare. |
Vol 75 - N° 2
P. 306-311 - agosto 2016 Ritorno al numero
Articolo precedente
- OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study
- Jon M. Hanifin, Charles N. Ellis, Ilona J. Frieden, Regina Fölster-Holst, Linda F. Stein Gold, Angelo Secci, Angela J. Smith, Cathy Zhao, Elena Kornyeyeva, Lawrence F. Eichenfield
- Inflamed skin predisposes to sensitization to less potent allergens
- Nita Kohli, Susan Nedorost
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?